A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients

Josep Guardia, Carlos Roncero, Jaime Galan, Begoña Gonzalvo, Teresa Burguete, Miquel Casas

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)

Abstract

The objective of this study was to determine whether quetiapine plus naltrexone is more effective than naltrexone alone for the treatment of alcohol-dependent patients. This was a double-blind, randomized clinical trial where eligible alcohol-dependent patients were randomized to receive naltrexone (50. mg/day) plus quetiapine (25-200. mg/day) or naltrexone (50. mg/day) plus placebo for 12. weeks, and afterwards patients received naltrexone alone during 4 additional weeks. The primary efficacy measures were percent days abstinent, drinks per drinking day, and the relapse rate. Sixty-two patients received a single-blind treatment with placebo plus naltrexone, and they were thereafter randomly assigned to quetiapine plus naltrexone (n. = 30) or placebo plus naltrexone (n. = 32). Eleven (36.7%) patients in the quetiapine-treated group and 4 (12.5%) patients in the placebo-treated group withdrew before they completed 12. weeks of treatment. There were no statistically significant differences for any primary drinking outcomes between treatment groups. Both regimens were well tolerated. This study failed to demonstrate any additional benefit from the combination of quetiapine and naltrexone compared to naltrexone alone on drinking outcomes. © 2010 Elsevier Ltd.
Original languageEnglish
Pages (from-to)265-269
JournalAddictive Behaviors
Volume36
Issue number3
DOIs
Publication statusPublished - 1 Mar 2011

Keywords

  • Alcohol-dependence
  • Antipsychotic
  • Combination
  • Craving
  • Naltrexone
  • Quetiapine

Fingerprint

Dive into the research topics of 'A double-blind, placebo-controlled, randomized pilot study comparing quetiapine with placebo, associated to naltrexone, in the treatment of alcohol-dependent patients'. Together they form a unique fingerprint.

Cite this